1.
Clin Diabetes
; 38(5): 474-485, 2020 Dec.
Article
in English
| MEDLINE
| ID: mdl-33384472
ABSTRACT
There are three automated insulin delivery devices on the U.S. market, two of which are currently approved by the U.S. Food and Drug Administration. These systems have already made a significant impact for the people who use them in improving diabetes outcomes, including glycemic control and hypoglycemia prevention. This article aims to help primary care and endocrinology providers better understand the components, differences, limitations, and potential fit of these systems into clinical practice.